Advanced in Febrile Neutropenia

Johanna U. Maenpaa

Pl 100, 
Tampere, FI 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Febrile Neutropenia
Pl 100, 
Tampere, FI 
OverviewLocationsClinical Research

Overview

Johanna Maenpaa practices in Tampere, Finland. Ms. Maenpaa is rated as an Advanced expert by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Febrile Neutropenia, Oophorectomy, and Salpingo-Oophorectomy.

Her clinical research consists of co-authoring 87 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Febrile Neutropenia.

Gender
Female

Locations

Pl 100, Tampere, 33014, Finland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 1/2, Open-label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase 1 and Phase 2) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase 1b) in Patients With Platinum Resistant or Refractory Ovarian Cancer
A Phase 1/2, Open-label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase 1 and Phase 2) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase 1b) in Patients With Platinum Resistant or Refractory Ovarian Cancer
Enrollment Status: Recruiting
Publish Date: May 13, 2025
Intervention Type: Biological, Drug
Study Drugs: TILT-123, Pembrolizumab
Study Phase: Phase 1/Phase 2
NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
View 2 Less Clinical Trial

87 Total Publications

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial.
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial.
Journal: Molecular oncology
Published: January 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Maenpaa's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile